Trimel Announces Voting Results for 2013 Annual Shareholders' Meeting
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 06/27/13 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the voting results from its annual general meeting held on June 27, 2013. The total number of shares represented in person or by proxy at the meeting was 89,096,694, representing 60.08% of Trimel's total issued and outstanding shares.
Shareholders voted in favour of the reappointment of the auditors of the company, and voted as follows in connection with the election of the directors of the company:
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the FDA for regulatory approval in the United States. For more information, please visit .
Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.06.2013 - 21:00 Uhr
Sprache: Deutsch
News-ID 274172
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Trimel Announces Voting Results for 2013 Annual Shareholders' Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Trimel Pharmaceuticals Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
